About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMGN - Amgen Inc.| Previous Close | $255.12 | Open | $252.87 |
| Volume | 3.34M | Market Cap | 150.074B |
| Yield | 2.33 % | Last Dividend | $5.95 |
| Appeals Court Affirms Validity Of Enbrel... | 07/01/20 |
| THOUSAND OAKS, Calif., July 1, 2020 /PRNewswire/ -- Amgen today announced that the United States Court of Appeals for the Federal Circuit has held in ... | |
| Amgen Stock Rises 5% | 07/01/20 |
| https://www.investing.com/news/stock-market-news/amgen-stock-rises-5-2217681 | |
| Insights & Forecast with Potential Impac... | 06/26/20 |
| The global cervical cancer therapeutics market size is expected to grow by USD 1.06 billion as per Technavio. This marks a significant market growth c... | |
| Buy these 3 stocks as they move above ke... | 06/23/20 |
| In a note published on Monday, Bank of America listed three stocks to buy on bullish technical breakouts. The stocks are on the verge or have already ... | |
| Amgen : Pandemic Pods and New Product La... | 06/22/20 |
| The people working at Amgen Dun Laoghaire faced a challenging situation when the COVID-19 pandemic began spreading around the globe. As a manufacturin... | |
| Amgen Is Supporting Advancement Of AMG 6... | 06/22/20 |
| THOUSAND OAKS, Calif., June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodies... | |
| What Ambani & RPG boss discuss on video-... | 06/22/20 |
| NEW DELHI: Two days after Reliance Industries Limited (RIL) announced it became a net-debt free company months ahead of its March 2021 target, Harsh G... | |
| RIL enters $ 150b club, highest mcap by ... | 06/20/20 |
| New Delhi: Reliance Industries Limited (RIL) has become the first Indian company to enter the exclusive club of $150 billion in market capitalisation ... | |
| Amgen To Present At The BMO Capital Mark... | 06/18/20 |
| THOUSAND OAKS, Calif., June 18, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healt... | |
| Antibody drugs to prevent and treat the ... | 06/11/20 |
| An antibody therapeutic could land in the sweet spot of the hunt for a coronavirus treatment. Several drug candidates have just started human testing ... | |
| Microsoft and a $5 billion Seattle biote... | 06/11/20 |
| Microsoft and the Seattle biotech Adaptive Biotechnologies have found "blind spots" on the coronavirus that could be good targets for vaccines. The te... | |
| Worldwide Anti-rheumatics Market to 2025... | 06/09/20 |
| DUBLIN--(BUSINESS WIRE)--The "Anti-rheumatics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added t... | |
| Here's how 13 top drugmakers are sprinti... | 06/08/20 |
| Leading drugmakers are researching treatments and vaccines for the novel coronavirus. The small biotech Moderna has leaped to the front of the race, w... | |
| Harvard wins Apple, Twitter backing on u... | 06/05/20 |
| Intel Corp., Apple and Amgen are among more than a dozen companies supporting Harvard University in a fierce legal battle that could shape the use of ... | |
| Coronavirus Vaccine Frontrunner Moderna ... | 06/04/20 |
| Moderna Inc (NASDAQ: MRNA ), which is on the cusp of starting a Phase 3 trial of its SARS-CoV-2 vaccine candidate mRNA-1273, announced a C-suite chang... | |
| The Zacks Analyst Blog Highlights: Novo ... | 06/01/20 |
| The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global | |
| The race for coronavirus treatments and ... | 06/01/20 |
| The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to w... | |
| Why Is Amgen (AMGN) Down 4% Since Last E... | 05/30/20 |
| Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Amgen Presents New AMG 510 Clinical Data... | 05/29/20 |
| THOUSAND OAKS, Calif., May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program e... | |
| Amgen To Present At The Jefferies 2020 V... | 05/28/20 |
| THOUSAND OAKS, Calif., May 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Jefferies 2020 Virtual Healthcare Conference at 4:00 p.m.... | |
| Alexion Stock Jumps on Signal That Fight... | 05/28/20 |
| Amgen has challenged Alexion???s exclusive rights to its blockbuster drug Soliris, a move that has been a significant worry for Alexion investors. A j... | |
| Bill Maris the founder of Google biotech... | 05/21/20 |
| Bill Maris, who founded Google Ventures and left to build his own investment fund called Section 32, has just brought aboard several ex-Googlers to hi... | |
| Amgen : Q4 2019 Financial Results | Mark... | 05/19/20 |
| Amgen Inc. GAAP to Non-GAAP Reconciliations ??? | May 19, 2020 | |
| Amgen (AMGN) Upgraded to Buy: What Does ... | 05/18/20 |
| Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stoc... | |
| Amgen Showcases Oncology Pipeline At ASC... | 05/13/20 |
| THOUSAND OAKS, Calif., May 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio wi... | |
| The Zacks Analyst Blog Highlights: Amgen... | 05/12/20 |
| The Zacks Analyst Blog Highlights: Amgen, BHP, Altria, Apple and Target | |
| Hold rating | 06/18/20 |
| JP Morgan maintains Neutral rating and raises Price Target from $219.00 to $225.00 | |
| Buy rating | 06/02/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $249.00 to $253.00 | |
| Strong Buy rating | 05/04/20 |
| and raises Price Target from $255.00 to $263.00 | |
| Buy rating | 05/01/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $219.00 to $249.00 | |
| Strong Buy rating | 05/01/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $267.00 to $280.00 | |
| Buy rating | 05/01/20 |
| and raises Price Target from $250.00 to $265.00 | |
| Strong Buy rating | 05/01/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $250.00 to $252.00 | |
| Hold rating | 05/01/20 |
| Wells Fargo maintains Equal-Weight rating and raises Price Target from $220.00 to $237.00 | |
| Buy rating | 05/01/20 |
| CFRA maintains Buy rating and raises Price Target from $223.00 to $259.00 | |
| Strong Buy rating | 04/27/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $240.00 to $250.00 | |
| Strong Buy rating | 04/15/20 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $277.00 to $267.00 | |
| Date | 2020-04-30 (AMC) | Est. (EPS/Rev.) | $3.76/ 5.98B |
| Actual (EPS/Rev.) | $4.17/ $6.16 B | EPS (TTM) | 12.84 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Options Eagle | George | 78.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Hi America | Lawrence | 62.00 % | Subscribe |
| LetsGrow - Growth Stocks | BigMoveTrader | 58.00 % | Follow |
| Fibonacci Trading | Arez | 56.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
